Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $46.09 Average Target Price from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $48.3636.

Several analysts recently weighed in on CAPR shares. Piper Sandler restated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday. B. Riley Financial upped their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Roth Mkm restated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday. Finally, Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $28.79 on Friday. The stock has a fifty day moving average price of $31.86 and a 200-day moving average price of $24.23. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -12.41 and a beta of 0.48. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Research analysts predict that Capricor Therapeutics will post -0.38 EPS for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the transaction, the director owned 7,529 shares of the company’s stock, valued at $240,928. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 172,529 shares of company stock valued at $5,302,440. 9.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of CAPR. Farther Finance Advisors LLC bought a new position in Capricor Therapeutics in the third quarter valued at about $28,000. Parkside Financial Bank & Trust bought a new position in Capricor Therapeutics in the third quarter valued at about $36,000. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the last quarter. ACT Capital Management LLC bought a new position in Capricor Therapeutics in the fourth quarter valued at about $43,000. Finally, KBC Group NV bought a new position in Capricor Therapeutics in the first quarter valued at about $44,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.